Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HLX35 in Advanced Solid Tumors
NCT05360381Phase 1Unknown
- Sponsor
- Henlius
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HLX35 in solid tumor (advanced stage) and squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Henlius. Primary endpoints: Incidence of Treatment-Related Adverse Events at 2 years, Proportion of patients experiencing dose limiting toxicity events at 28 days and 2 more. Status: unknown.
02
Drugs
HLX35
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05360381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360381.